Search
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalFood and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. … Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsFibrinolysin
go.drugbank.com/drugs/DB05254InvestigationalFibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. … Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond.
Categories: Enzymes and Coenzymes, Blood and Blood Forming OrgansSilver nitrate
go.drugbank.com/drugs/DB11080ApprovedSilver nitrate is an inorganic compound with the chemical formula AgNO3. In its solid form, silver nitrate is coordinated in a trigonal planar arrangement. … It is used in making photographic films, and in laboratory setting as a staining agent in protein visualization in PAGE gels and in scanning electron microscopy.
Categories: Antiseptics and DisinfectantsArmodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalArmodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. … Food and Drug Administration (FDA) in June 2007.
Categories: Modafinil and isomer, Metabolic Side Effects of Drugs and SubstancesTriclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.
Categories: Antiparasitic Products, Insecticides and RepellentsGPI-0100
go.drugbank.com/drugs/DB05929InvestigationalThe GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsSemzuvolimab
go.drugbank.com/drugs/DB18920InvestigationalSemzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).
Categories: Amino Acids, Peptides, and ProteinsEtranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … [L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity.
Categories: Cellular and Gene Therapy, Blood and Blood Forming OrgansDihydroergocristine
go.drugbank.com/drugs/DB13345Approved[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.
Categories: Ergot Alkaloids and Derivatives